Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

Crispr Therapeutics (CRSP) announced that its COO, Julianne Bruno, will be stepping down from the company to pursue external opportunities, ...

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Expanding CRISPR's Potential Since its discovery, CRISPR (“Clustered Regularly Interspaced Short Palindromic Repeats”), which ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.